Finance

Lists
Portfolios
Track your investments in one place, get AI insights, and more
Top movers in your lists
Symbols
Symbols
Price
Change
% Change
Trend
Prev Close
Open
High
Low
Volume
Mkt Cap
SIXT
Technology
SIXT
Technology
SIXT
-2.45%
3,736.96
-93.82
-2.45%
3,830.783,759.433,775.453,712.07
SIXE
Energy
SIXE
Energy
SIXE
+1.68%
1,335.53
+22.10
+1.68%
1,313.431,321.431,336.731,321.43
SIXV
Health care
SIXV
Health care
SIXV
+1.59%
1,713.50
+26.78
+1.59%
1,686.721,692.211,719.801,692.21
SIXI
Industrials
SIXI
Industrials
SIXI
-1.46%
1,849.21
-27.34
-1.46%
1,876.551,867.711,867.711,848.92
SIXR
Staples
SIXR
Staples
SIXR
+1.02%
863.33
+8.69
+1.02%
854.64861.53869.70859.37
US market summary
Major U.S. stock indices concluded their third consecutive session in negative territory, driven primarily by a notable selloff in artificial intelligence and semiconductor companies. Heavyweights in the tech-heavy Nasdaq Composite and broader S&P 500 experienced significant downward pressure, shifting momentum away from the record market highs established earlier in the month.
Dive deeper with AI
Global sovereign bond yields hover at multiyear highs amid inflation anxiety
Government bond yields across the United States, Europe, and Japan surged to levels not seen in decades before showing signs of stabilization. The rapid increase in yields has been heavily driven by fiscal deficit expansions, higher energy costs, and massive debt-funded capital expenditures originating from the capital-intensive artificial intelligence industry.
Dive deeper with AI
Middle East tensions elevate oil prices following expired truce
Geopolitical friction in the Middle East has intensified after a 60-day ceasefire between the United States and Iran expired without a permanent resolution. The gridlock, alongside active maritime disruptions in the crucial Strait of Hormuz, has kept crude oil futures elevated around the $85 to $91 per barrel range, stoking broader market fears of prolonged inflation.
Dive deeper with AI
Moderna shares skyrocket following milestone cancer vaccine trial results
Shares of Moderna more than doubled in early trading following a highly successful Phase 3 clinical trial conducted in tandem with pharmaceutical partner Merck. The study evaluated their individualized mRNA-based cancer vaccine in combination with Keytruda, successfully meeting its primary goal of recurrence-free survival in advanced melanoma patients.
Dive deeper with AI
AI content may include mistakes. Learn more
AI content may include mistakes. Learn more
Google apps